IDH wild-type

CRT significantly improves survival in IDH-wt/TERTp-mut grade 2 to 3 gliomas with favorable safety.

IFI44 may drive glioma progression through dual mechanisms of immune microenvironment remodeling and promotion of tumor cell aggressiveness, supporting its potential as a prognostic biomarker and therapeutic target. Although preliminary knockdown and overexpression assays were performed, the underlying mechanisms of IFI44-mediated immune regulation and tumor progression require further investigation.

Both pre- and postoperative models successfully predict short-term recurrence in elderly glioma patients. Key clinical risk factors, such as tumors infiltrating the corpus callosum and various tumor-related symptoms were identified. Additionally, certain common postoperative physical and psychological symptom changes in the MDASI-BT may be predictive markers for long-term relapse. A crucial finding is that the factors associated with recurrence are distinct across molecular subtypes, underscoring the need for subtype-specific risk management.

The identified qMSP cut-off value (0.242) based on the procedure described in this study provides a robust prognostic stratification tool for GBM patients. High MGMT methylation correlates with improved survival, supporting its integration into clinical decision-making. Further multi-center validation studies are warranted to establish standardized MGMT assessment methodologies.

P1/2, N=42, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jan 2032 --> Apr 2028

IDH1 inhibition reverses resistance-mediated chromatin changes and enables radiation re-sensitization. Ultimately, these findings demonstrate the efficacy of single-cell multiome analysis in elucidating resistance mechanisms and identifying targetable pathways for MYC-driven medulloblastoma.

We selected six of these inhibitors for further investigation, evaluating their effects both alone and in combination with TMZ in commercially available U87 MG wild-type and IDH1 mutant (IDH1 WT and MUT) glioma cells and patient-derived cells established from glioma organoids (GBO-PDC). This study highlights the therapeutic potential of RNaseH2 inhibition in combination with TMZ for GBM therapy, validated in patient-derived model, offering a promising avenue for treating this highly aggressive and yet uncurable cancer.

P2/3, N=144, Active, not recruiting, Laminar Pharmaceuticals | Trial completion date: May 2025 --> Nov 2026 | Trial primary completion date: Oct 2024 --> Jan 2026

P=N/A, N=18, Suspended, Royal Adelaide Hospital | Recruiting --> Suspended

An RTV of 1.75 cm3 confers optimal survival benefit in IDH wildtype GBM. A threshold RTV of 1.75 cm3 in methylated and 2.50 cm3 in unmethylated IDH wildtype GBM confers optimal survival benefit. Our findings suggest that RTV may be a more accurate prognostic tool than EOR and could guide surgical decision-making.

Elevated sCD163 levels in CSF were positively associated with various TNFSFs and sTNFRs and inversely associated with type 1 IFNs and various ILs, suggesting a dominant influence of tumor associated M2 macrophages on the TME. The sCD163/type I IFN ratio may serve as a potential prognostic indicator in patients with IDH-wildtype glioblastoma.

Inhibiting IDH mutations with vorasidenib lowers D-2HG and is beneficial to patients. Other drugs like ONC201 and metformin can metabolically suppress oncogenic chromatin states in pediatric gliomas. This dynamic cross talk between metabolism and epigenetics not only underpins tumor biology but also presents opportunities for innovative therapeutic strategies.